tbuckley/cabot-search huggingface dataset:
Citrullinated Aggrecan Epitopes as Targets of Autoreactive <scp>CD</scp>4+ T Cells in Patients With Rheumatoid Arthritis
Authors: Cliff Rims, Hannes Uchtenhagen, Mariana J. Kaplan, Carmelo Carmona‐Rivera, Philip Carlucci, Katalin Mikecz, Adrienn Markovics, Jeffrey Carlin, Jane H. Buckner, Eddie A. James
Journal: Arthritis & Rheumatology (2018)

Recognition of citrullinated antigens such as vimentin, fibrinogen, and α-enolase is associated with rheumatoid arthritis (RA). Emerging data suggest that the matrix protein aggrecan is also recognized as a citrullinated antigen. This study was undertaken to directly visualize Cit-aggrecan-specific T cells and characterize them in patients with RA.Citrullinated aggrecan peptides with likely DRB1*04:01 binding motifs were predicted using a previously published scanning algorithm. Peptides with detectable binding were assessed for immunogenicity by HLA tetramer staining, followed by single cell cloning. Selectivity for citrullinated peptide was assessed by tetramer staining and proliferation assays. Ex vivo tetramer staining was then performed to assess frequencies of aggrecan-specific T cells in peripheral blood. Finally, disease association was assessed by comparing T cell frequencies in RA patients and controls and correlating aggrecan-specific T cells with levels of aggrecan-specific antibodies.We identified 6 immunogenic peptides, 2 of which were the predominant T cell targets in peripheral blood. These 2 epitopes were citrullinated at HLA binding residues and shared homologous sequences. RA patients had significantly higher frequencies of Cit-aggrecan-specific T cells than healthy subjects. Furthermore, T cell frequencies were significantly correlated with antibodies against citrullinated aggrecan.Our findings indicate that T cells that recognize citrullinated aggrecan are present in patients with RA and correlate with antibodies that target this same antigen. Consequently, aggrecan-specific T cells and antibodies are potentially relevant markers that could be used to monitor patients with RA or at-risk subjects.
Assessment of Proposed Changes to Evaluation and Management Billing Levels by Physician Specialty
Authors: Brian C. Callaghan, James F. Burke, Lesli E. Skolarus, Kevin A. Kerber
Journal: JAMA Neurology (2018)

This study compares the current billing levels across specialties to estimate the financial impact of the proposal to collapse payment amounts for levels 2 to 5 evaluation and management services into single payments.
Exclusive expression of transmembrane TNF aggravates acute glomerulonephritis despite reduced leukocyte infiltration and inflammation
Authors: Martin B. Müller, John M. Hoppe, Andrei Bideak, Moritz Lux, Maja T. Lindenmeyer, Susanna Müller, Nuru Eltrich, Bernhard Ryffel, Volker Vielhauer
Journal: Kidney International (2018)
Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study
Authors: Youn H. Kim, H. Miles Prince, Sean Whittaker, Steven M. Horwitz, Madeleine Duvic, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, Lauren C. Pinter-Brown, Pablo L. Ortiz-Romero, Oleg E. Akilov, Judith Trotman, Kerry Taylor, Michael Weichenthal, Jan Walewski, David C. Fisher, Marise McNeeley, Alejandro A. Gru, Yinghui Wang, Maria Corinna Palanca-Wessels, Julie Lisano, Martha Li, Hui-Min Lin, Meredith Little, William L. Trepicchio, Reinhard Dummer
Journal: Blood (2018)
Risk factors for treatment failure in scabies: a cohort study
Authors: A. Aussy, E. Houivet, V. Hébert, H. Colas‐Cailleux, N. Laaengh, C. Richard, M. Ouvry, C. Boulard, S. Léger, N. Litrowski, J. Benichou, P. Joly, S. Bechu, N. Mion‐Mouton, O. Lafaurie, A. Barrel, M. Pulluard, V. Hamel, M.X. Dore, E. Duflo, S. Lardans‐Cassius, J.C. Rzeznik, S. Baricault
Journal: British Journal of Dermatology (2018)

Treatment failure, which occurs in about one‐third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. To identify predictors of treatment failure of scabies in ambulatory populations. This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22–3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49–23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89–9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50–21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34–14·9), mattresses (OR 4·16, 95% CI 1·35–12·8) or car seats (OR 6·57, 95% CI 3·27–13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57–10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71–16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55–7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96–16·7). Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression
Authors: Henning Bundgaard, Christian Jøns, Elisabeth M Lodder, Jose M G Izarzugaza, Jose A Romero Herrera, Steen Pehrson, Jacob Tfelt-Hansen, Gustav Ahlberg, Morten S Olesen, Anders G Holst, Hein Wellens, Carin de Villiers, Robert Hastings, Graham Stuart, Søren Brunak, Arthur A M Wilde, Hugh Watkins, Alex H Christensen
Journal: New England Journal of Medicine (2018)

A Novel Familial Cardiac Arrhythmia Syndrome Five families were identified with a novel autosomal dominant syndrome characterized by marked ST-segment depression, the development of atrial fibrilla...
Disparities in mortality among 25–44-year-olds in England: a longitudinal, population-based study
Authors: Evangelos Kontopantelis, Iain Buchan, Roger T Webb, Darren M Ashcroft, Mamas A Mamas, Tim Doran
Journal: The Lancet Public Health (2018)

BackgroundSince the mid-1990s, excess mortality has increased markedly for adults aged 25–44 years in the north compared with the south of England. We examined the underlying causes of this excess mortality and the contribution of socioeconomic deprivation.MethodsMortality data from the Office of National Statistics for adults aged 25–44 years were aggregated and compared between England's five most northern versus five most southern government office regions between Jan 1, 1981, and Dec 31, 2016. Poisson regression models, adjusted for age and sex, were used to quantify excess mortality in the north compared with the south by underlying cause of death (accidents, alcohol related, cardiovascular disease and diabetes, drug related, suicide, cancer, and other causes). The role of socioeconomic deprivation, as measured by the 2015 Index of Multiple Deprivation, in explaining the excess and regional variability was also explored.FindingsA mortality divide between the north and south appeared in the mid-1990s and rapidly expanded thereafter for deaths attributed to accidents, alcohol misuse, and drug misuse. In the 2014–16 period, the northern excess was incidence rate ratio (IRR) 1·47 (95% CI 1·39–1·54) for cardiovascular reasons, 2·09 (1·94–2·25) for alcohol misuse, and 1·60 (1·51–1·70) for drug misuse, across both men and women aged 25–44 years. National mortality rates for cardiovascular deaths declined over the study period but a longstanding gap between north and south persisted (from 33·3 [95% CI 31·8–34·8] in 1981 to 15·0 [14·0–15·9] in 2016 in the north vs from 23·5 [22·3–24·8] to 9·9 [9·2–10·5] in the south). Between 2014 and 2016, estimated excess numbers of death in the north versus the south for those aged 25–44 years were 1881 (95% CI 726–2627) for women and 3530 (2216–4511) for men. Socioeconomic deprivation explained up to two-thirds of the excess mortality in the north (IRR for northern effect reduced from 1·15 [95% CI 1·14–1·15; unadjusted] to 1·05 [1·04–1·05; adjusted for Index of Multiple Deprivation]). By 2016, in addition to the persistent north–south gap, mortality rates in London were lower than in all other regions, with IRRs ranging from IRR 1·13 (95% CI 1·12–1·15) for the East England to 1·22 (1·20–1·24) for the North East, even after adjusting for deprivation.InterpretationSharp relative rises in deaths from cardiovascular reasons, alcohol misuse and drug misuse in the north compared with the south seem to have created new health divisions between England's regions. This gap might be due to exacerbation of existing social and health inequalities that have been experienced for many years. These divisions might suggest increasing psychological distress, despair, and risk taking among young and middle-aged adults, particularly outside of London.FundingMedical Research Council and Wellcome Trust.
DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury
Authors: Dawei Jiang, Zhilei Ge, Hyung-Jun Im, Christopher G. England, Dalong Ni, Junjun Hou, Luhao Zhang, Christopher J. Kutyreff, Yongjun Yan, Yan Liu, Steve Y. Cho, Jonathan W. Engle, Jiye Shi, Peng Huang, Chunhai Fan, Hao Yan, Weibo Cai
Journal: Nature Biomedical Engineering (2018)
Abstract 12277: Angiopoietin-Like Protein2 (angptl2)-Induced Vascular Inflammation Causes the Progression of Endothelial Dysfunction and Atherosclerosis
Authors: Eiji Horio, Koichi Kaikita, Keishi Miyata, Tsuyoshi Kadomatsu, Hirokazu Tazume, Tian Zhe, Yuji Miyazaki, Takamichi Ono, Koji Sato, Kenichi Tsujita, Shinji Tayama, Seiji Hokimoto, Seigo Sugiyama, Hiroyuki Hao, Motohiro Takeya, Hisao Ogawa, Yuichi Oike
Journal: Circulation (2011)

Chronic vascular inflammation in coronary artery plays crucial roles in pathogenesis of coronary artery disease, however the molecular mechanisms have not been fully clarified. Recently, we reporte...
Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene.
Authors: X. Gong, J. Du, S.H. Parsons, F.F. Merzoug, Y. Webster, P.W. Iversen, L.C. Chio, R.D. Van Horn, X. Lin, W. Blosser, B. Han, S. Jin, S. Yao, H. Bian, C. Ficklin, L. Fan, A. Kapoor, S. Antonysamy, A.M. Mc Nulty, K. Froning, D. Manglicmot, A. Pustilnik, K. Weichert, S.R. Wasserman, M. Dowless, C. Marugan, C. Baquero, M.J. Lallena, S.W. Eastman, Y.H. Hui, M.Z. Dieter, T. Doman, S. Chu, H.R. Qian, X.S. Ye, D.A. Barda, G.D. Plowman, C. Reinhard, R.M. Campbell, J.R. Henry, S.G. Buchanan
Journal: Cancer Discovery (2019)

Loss-of-function mutations in the retinoblastoma gene RB1 are common in several treatment-refractory cancers such as small-cell lung cancer and triple-negative breast cancer. To identify drugs synthetic lethal with RB1 mutation (RB1mut), we tested 36 cell-cycle inhibitors using a cancer cell panel profiling approach optimized to discern cytotoxic from cytostatic effects.  Inhibitors of the Aurora kinases, AurA and AurB, showed the strongest RB1 association in this assay. LY3295668, an AurA inhibitor with over 1000-fold selectivity versus AurB, is distinguished by minimal toxicity to bone marrow cells at concentrations active against RB1mut cancer cells and leads to durable regression of RB1mut tumor xenografts at exposures that are well tolerated in rodents.  Genetic suppression screens identified enforcers of the spindle assembly checkpoint (SAC) as essential for LY3295668 cytotoxicity in Rb-deficient cancers and suggest a model in which a primed SAC creates a unique dependency on AurA kinase for mitotic exit and survival.
Abstract 12459: Fibroblast Growth Factor-23 and Incident Heart Failure With Reduced versus Preserved Ejection Fraction in the Multi Ethnic Study of Atherosclerosis
Authors: Mohamed Faher Almahmoud, Elsayed Z Soliman, Alain G Bertoni, Bryan Kestenbaum, Ronit Katz, Joao A Lima, Pamela Ouyang, Paul E Miller, Erin D Michos, David M Herrington
Journal: Circulation (2016)

Introduction: Higher FGF-23 levels are associated with incident heart failure (HF) in the Multi-Ethnic Study of Atherosclerosis. FGF-23 is also associated with left ventricular hypertrophy and diffuse myocardial fibrosis in experimental models. Whether FGF-23 association with HF is similar for reduced (HFrEF) and preserved (HFpEF) ejection fraction is not well established. Hypothesis: Higher FGF-23 levels are associated with increased risk of HFpEF. Methods: We studied 6,549 participants (mean age 62 ± 10 yrs, 53% women, mean eGFR of 81 ± 18 m,/min/1.53m 2 ) from the Multi-Ethnic Study of Atherosclerosis (MESA) who were free of cardiovascular disease at baseline (2000-2002). HF events were ascertained by an adjudication committee for a mean follow-up of 11.1 years. We classified HF events as HFrEF (ejection fraction (EF) &lt;50%) or HFpEF (EF ≥50%) at the time of diagnosis. Cox proportional hazard regression was used to compute hazard ratios (HR) and 95% confidence intervals (CI) for the association between baseline serum FGF-23 and incident HFrEF and HFpEF. Models were adjusted for age, sex, race/ethnicity, education, study site, smoking, diabetes, systolic blood pressure, use of antihypertensive medications, HDL-C, LDL-C, C-reactive protein, eGFR, and log urine albumin creatinine ratio. Results: A total of 227 HF events occurred during follow-up, of which 125 were classified as HFrEF. In the fully adjusted model, associations of FGF-23 with heart failure events tended to be stronger for HFpEF than for HFrEF (HR 2.1 vs. 1.5 per doubling of FGF-23; Table). However, these associations were not statistically distinguishable. Conclusion: FGF-23 association with HF is stronger for HFpEF than HFrEF in a population-based cohort. The qualitative difference in strength of associations of FGF-23 with HFpEF and HFrEF is consistent with experimental data demonstrating effects of recombinant FGF-23 on cardiac hypertrophic pathways.
Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies
Authors: Zhi-Hao Wang, Pai Liu, Xia Liu, Shan Ping Yu, Jian-Zhi Wang, Keqiang Ye
Journal: The Journal of Experimental Medicine (2018)

SRPK2 is abnormally activated in tauopathies including Alzheimer’s disease (AD). SRPK2 is known to play an important role in pre–mRNA splicing by phosphorylating SR-splicing factors. Dysregulation of tau exon 10 pre–mRNA splicing causes pathological imbalances in 3R- and 4R-tau, leading to neurodegeneration; however, the role of SRPK2 in these processes remains unclear. Here we show that delta-secretase (also known as asparagine endopeptidase; AEP), which is activated in AD, cleaves SRPK2 and increases its nuclear translocation as well as kinase activity, augmenting exon 10 inclusion. Conversely, AEP-uncleavable SRPK2 N342A mutant increases exon 10 exclusion. Lentiviral expression of truncated SRPK2 increases 4R-tau isoforms and accelerates cognitive decline in htau mice. Uncleavable SRPK2 N342A expression improves synaptic functions and prevents spatial memory deficits in tau intronic mutant FTDP-17 transgenic mice. Hence, AEP mediates tau-splicing imbalance in tauopathies via cleaving SRPK2.
Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial
Authors: Edward Agura, Boglarka Gyurkocza, Rajneesh Nath, Mark R. Litzow, Benjamin K. Tomlinson, Sunil Abhyankar, Stuart Seropian, Patrick J. Stiff, Hannah K. Choe, Partow Kebriaei, James M. Foran, George Chen, Moshe Yair Levy, Hillard M Lazarus, Sergio Giralt, Mark S. Berger, Vijay Reddy, John M. Pagel
Journal: Blood (2018)
Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010–2017: a nationwide surveillance study
Authors: J.G. Liese, C. Schoen, M. van der Linden, L. Lehmann, D. Goettler, S. Keller, A. Maier, F. Segerer, M.A. Rose, A. Streng
Journal: Clinical Microbiology and Infection (2018)

Parapneumonic pleural effusions/empyema (PPE/PE) are severe complications of community-acquired pneumonia. We investigated the bacterial aetiology and incidence of paediatric PPE/PE in Germany after the introduction of universal pneumococcal conjugate vaccine (PCV) immunization for infants.Children <18 years of age hospitalized with pneumonia-associated PPE/PE necessitating pleural drainage or persisting >7 days were reported to the German Surveillance Unit for Rare Diseases in Childhood between October 2010 and June 2017. All bacteria detected in blood or pleural fluid (by culture/PCR) were included, with serotyping for Streptococcus pneumoniae.The median age of all 1447 PPE/PE patients was 5 years (interquartile range 3-10). In 488 of the 1447 children with PPE/PE (34%), 541 bacteria (>40 species) were detected. Aerobic gram-positive cocci accounted for 469 of 541 bacteria detected (87%); these were most frequently Streptococcus pneumoniae (41%), Streptococcus pyogenes (19%) and Staphylococcus aureus (6%). Serotype 3 accounted for 45% of 78 serotyped S. pneumoniae strains. Annual PPE/PE incidence varied between 14 (95%CI 12-16) and 18 (95%CI 16-21) PPE/PE per million children. Incidence of S. pneumoniae PPE/PE decreased from 3.5 (95%CI 2.5-4.6) per million children in 2010/11 to 1.5 (95%CI 0.9-2.4) in 2013/14 (p 0.002), followed by a re-increase to 2.2 (95%CI 1.5-3.2) by 2016/17 (p 0.205).In the era of widespread PCV immunization, cases of paediatric PPE/PE were still caused mainly by S. pneumoniae and, increasingly, by S. pyogenes. The re-increase in the incidence of PPE/PE overall and in S. pneumoniae-associated PPE/PE indicates ongoing changes in the bacterial aetiology and requires further surveillance.
Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy
Authors: H. Kim Lyerly, Takuya Osada, Zachary C. Hartman
Journal: Clinical Cancer Research (2018)

Systemic IL12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL12 to the tumor microenvironment appears promising in a first-in-human study, appearing to stimulate tumor-specific adaptive immune responses with minimal systemic toxicity.See related article by Strauss et al., p. 99.
Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
Authors: Max S. Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Kroenke, Thierry Facon, Hermann Einsele, Gerd Munzert
Journal: Blood (2018)
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)
Authors: Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Ursula Vehling-Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Christina Peveling genannt Reddemann, Ullrich Graeven, Gunter Schuch, Ingo Schwaner, Arndt Stahler, Andreas Jung, Thomas Kirchner, Swantje Held, Sebastian Stintzing, Clemens Giessen-Jung, Volker Heinemann
Journal: Journal of Clinical Oncology (2018)

The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront use of fluoropyrimidine plus irinotecan plus bevacizumab (arm B) in a 1:1 randomized, controlled phase III trial.The primary efficacy end point was time to failure of the strategy (TFS). Given a 90% CI, a power of 70%, and a one-sided α of .05, the margin for noninferiority was set at 0.8. In the case of demonstrated noninferiority of TFS, an analysis of symptomatic toxicities during TFS would define the superior strategy. Secondary end points included the effect of molecular subgroups on efficacy parameters.A total of 421 randomly assigned patients (arm A: n = 212; arm B: n = 209) formed the full analysis set. Median age was 71 and 69 years, respectively. Noninferiority of TFS was not shown (hazard ratio [HR], 0.86; 90% CI, 0.73 to 1.02). In detail, patients with RAS/BRAF wild-type tumors benefitted from combination chemotherapy (HR, 0.61; 90% CI, 0.46 to 0.82; P = .005), whereas patients with RAS mutant tumors (HR, 1.09; 90% CI, 0.81 to 1.46; P = .58) did not (Cox model for interaction of study arm and RAS status: P = .03). Comparable results were obtained for overall survival.Noninferiority of sequential escalation therapy compared with initial combination chemotherapy could not be demonstrated for TFS. RAS status may be important to guide therapy as treatment of patients with upfront combination therapy was clearly superior in RAS/BRAF wild-type tumors, whereas sequential escalation chemotherapy seems to provide comparable results in patients with RAS mutant tumors.
Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Authors: Tim A. Labeur, Jeroen L.A. van Vugt, David W.G. Ten Cate, R. Bart Takkenberg, Jan N.M. IJzermans, Bas Groot Koerkamp, Robert A. de Man, Otto M. van Delden, Ferry A.L.M. Eskens, Heinz-Josef Klümpen
Journal: Liver Cancer (2018)

Previous studies have suggested body composition as a predictor of sorafenib toxicity and outcome in patients with advanced hepatocellular carcinoma (HCC). Large studies on the impact of body composition parameters in European HCC patients are lacking. Our aim was to validate the prognostic value of body composition parameters in Dutch patients with HCC treated with sorafenib.A retrospective analysis was performed in a cohort of HCC patients treated with sorafenib at two Dutch tertiary referral centers between 2007 and 2016. Body composition (adipose and skeletal muscle tissue) was measured at baseline by computed tomography (CT). Low skeletal muscle mass (SMM) and density were defined using published cut-offs. Body composition parameters were correlated with overall survival (OS), time to progression, response rate, and toxicity.A total of 278 patients were included, mostly Child-Pugh class A (85%) and Barcelona Clinic Liver Cancer (BCLC) stage C (73%), with a median OS of 9.5 months (95% CI 8.1-11.0). Patients with combined low SMM and low total adipose tissue index (TATI) (n = 68, 25%) had a poor median OS (5.8, 95% CI 4.8-6.8) compared with other patients (11.7, 95% CI 9.4-14.0). Combined low SMM and low TATI remained an independent predictor of OS (HR 1.56, 95% CI 1.15-2.11, p = 0.004) after adjusting for known prognostic factors. There was no association between body composition and sorafenib toxicity.In Dutch HCC patients treated with sorafenib, the combined presence of low SMM and low TATI was associated with impaired survival, independent of known prognostic factors. CT assessment of body composition may provide additional prognostic information prior to sorafenib treatment.
Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101
Authors: Divaya Bhutani, Siyang Leng, Andrew Eisenberger, Mathew S. Maurer, Sofia Shames, Jeff Goldsmith, Suzanne Lentzsch
Journal: Blood (2018)